Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
11 studies found for:    "Polycystic liver disease"
Show Display Options
Rank Status Study
1 Completed Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
Condition: Polycystic Liver Disease
Intervention: Drug: Lanreotide Autogel 90 mg and 120 mg
2 Terminated
Has Results
Polycystic Liver Disease in Kidney Transplant
Condition: Polycystic Liver Disease
Interventions: Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil;   Drug: Prednisone
3 Unknown  Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
Condition: Polycystic Liver Disease
Intervention: Other: PLD-Q
4 Completed Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
Conditions: Polycystic Liver Disease (PLD):;   Polycystic Kidney, Autosomal Dominant;   Polycystic Liver Disease
Intervention: Drug: Ursodeoxycholic Acid
5 Active, not recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
6 Completed Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
Condition: Polycystic Liver Disease
Intervention: Drug: Lanreotide
7 Completed Everolimus and LongActing Octreotide Trial in Polycystic Livers
Condition: Polycystic Liver Disease
Interventions: Drug: Everolimus;   Drug: Octreotide LAR
8 Completed
Has Results
Octreotide in Severe Polycystic Liver Disease
Conditions: Polycystic Kidney, Autosomal Dominant;   Polycystic Liver Disease;   Hepatomegaly;   Liver Diseases;   Kidney, Polycystic;   Abdominal Pain
Interventions: Drug: Octreotide;   Drug: Placebo
9 Completed Lanreotide as Treatment of Polycystic Livers
Conditions: Polycystic Liver Disease;   Hepatomegaly;   Liver Diseases;   Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Placebo;   Drug: Lanreotide
10 Unknown  Open-Label Extension of LOCKCYST Trial
Conditions: Polycystic Liver Disease;   Hepatomegaly;   Liver Diseases;   Polycystic Kidney;   Autosomal Dominant
Intervention: Drug: lanreotide
11 Completed The Vienna RAP Pilot Study
Condition: ADPKD
Intervention: Drug: Sirolimus

Study has passed its completion date and status has not been verified in more than two years.